第十一批国家药品集采开标，华纳药厂盐酸贝尼地平片拟中选

Group 1 - The core point of the article is the successful selection of Hunan Warner Pharmaceutical Co., Ltd.'s Benidipine Hydrochloride Tablets in the 11th batch of national centralized drug procurement, highlighting the company's competitive edge in the pharmaceutical market [1][2] - The centralized procurement included 55 types of commonly used drugs across various therapeutic areas, with participation from 4.6 million medical institutions and 445 companies submitting bids [1] - Benidipine Hydrochloride Tablets are a long-acting third-generation dihydropyridine calcium antagonist used for treating primary hypertension and angina, addressing a significant health concern in China where cardiovascular diseases affect 330 million people [2] Group 2 - The national procurement emphasizes "stabilizing clinical use and ensuring quality," raising the quality control standards for participating companies [3] - Warner Pharmaceutical has maintained a 100% pass rate in national quality inspections for its procurement products, establishing a strong quality brand [3] - The company has actively embraced centralized procurement policies, with 22 products selected in national or regional procurements, demonstrating its adaptability to policy changes [3]